The data indicates a consistent upward trend in diabetes medicine sales in Sweden from 2024 to 2028, expressed in US Dollars PPP Per Capita. The values for these years are projected as follows: 2024: 47.7, 2025: 52.6, 2026: 57.4, 2027: 62.2, and 2028: 67.1. Year-on-year percentage increases are projected around 10% from 2024 onwards. The Compound Annual Growth Rate (CAGR) over the five-year period from 2024 to 2028 is approximately 8.7%.
Future trends to watch for include further development in diabetes management technologies, potential regulatory changes affecting pharmaceutical pricing, and healthcare policy reforms in Sweden. Additionally, keep an eye on demographic shifts, such as an aging population, which may impact the demand for diabetes medications.
